Atossa Therapeutics (NASDAQ:ATOS) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOSFree Report) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

A number of other analysts have also recently weighed in on ATOS. Cantor Fitzgerald reaffirmed an overweight rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. StockNews.com cut shares of Atossa Therapeutics from a hold rating to a sell rating in a research report on Monday, March 18th.

Check Out Our Latest Stock Report on Atossa Therapeutics

Atossa Therapeutics Trading Down 8.0 %

Shares of Atossa Therapeutics stock opened at $1.84 on Tuesday. Atossa Therapeutics has a 12-month low of $0.59 and a 12-month high of $2.11. The stock has a market cap of $230.55 million, a PE ratio of -7.67 and a beta of 1.19. The company has a 50-day moving average of $1.17 and a two-hundred day moving average of $0.90.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in shares of Atossa Therapeutics by 29.3% in the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock valued at $395,000 after purchasing an additional 101,690 shares in the last quarter. Northern Trust Corp grew its position in Atossa Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock worth $201,000 after purchasing an additional 13,280 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Atossa Therapeutics in the 3rd quarter worth about $98,000. UBS Group AG bought a new position in Atossa Therapeutics in the 3rd quarter worth about $25,000. Finally, XTX Topco Ltd bought a new position in Atossa Therapeutics in the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Articles

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.